DOCSLIB.ORG

Information to Users

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information to Users INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, If unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. ProQuest Information and Learning 300 North Zeeb Road, Ann Arbor, Ml 48106-1346 USA 800-521-0600 UMI* STRUCTURAL PROBES OF RETINOID ACTION DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Kevin L. Weiss, B.S., R.Ph. ***** The Ohio State University 2001 Dissertation Committee: Approved by Robert W. Curley, Jr., Ph.D., Adviser Robert W. Brueggemeier, Ph.D. Adviser Larry W. Robertson, Ph.D. College of Pharrfiacy UMI Number 3011160 __ ® UMI UMI Microform 3011160 Copyright 2001 by Bell & Howell Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. Bell & Howell Information and teaming Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT In cancer chemoprevention studies, 4-hydroxyphenylretlnamide (4-HPR) has been shown to be a less toxic, more effective analog of retinoic acid (RA). In tumor cells, research has shown that the biological effects of 4-HPR differ in some ways from retinoic acid. Most investigators find that 4-HPR does not bind to retinoic acid receptors (RARs) and that it induces apoptosis while RA induces differentiation. In order to explore the possibility that the RA-like effects of 4-HPR may be in part due to hydrolysis, we have synthesized 4-hydroxybenzylretinone (4-HBR). Furthermore, previous studies have shown that 4-HPR-O-glucuronide is more potent and less toxic than 4-HPR. The higher potency and lower toxicity of this glucuronide suggests that 4-HBR-O-glucuronide may also provide an in vivo chemotherapeutic advantage. The synthesis of this derivative is also presented. Retinoic acid is thought to support animal growth and cellular differentiation by binding to the RARs. The precursor to RA, retinol (ROL), is not believed to directly activate the RARs. However, our collaborators have previously reported that ROL is only 4 to 7 fold less potent than RA in competing with [^H]-RA for binding to the RARs. In order to further examine the structure activity relationships of such RAR-binding, we have prepared a series of ROL analogs that cannot be readily oxidized to retinoic acid. In addition, another group has recently reported that 4-oxoretinol also binds to the retinoic acid receptors. An improved synthesis of this material is presented. The C-linked analog of retinoyl-p-glucuronide has previously been synthesized in our laboratory. Unfortunately, the known route to this analog is lengthy and suffers from poor isomeric purity of the final product. It has been envisioned that this analog may be synthesized by alkylation of a retinoid acyl anion equivalent that was utilized in the synthesis of 4-HBR and its O- glucuronide. Preliminary investigations toward the newly proposed synthesis are described. Ill DEDICATION ca. 1946 Dedicated to my family IV ACKNOWLEDGMENTS The author wishes to acknowledge his family, loved ones, friends, collaborators and co-workers. Thank you for your guidance and support prior to and throughout graduate school. Mom and Dad Joan Dandrea Kristin Jack Fowble Grandparents Dr. Witiak Kim Dr. Curley Jon Dr. Brueggemeier Tim and Michele Dr. Robertson Sherry and Mike Dr. Abou-lssa and co-workers Tim and Stacy Dr. Clagett-Dame and co-workers L.V. teachers and friends Dr. Albert Awad Susan Dr. Stephen Cutler Kalyan Dr. Michael Milks Venki Maureen Gearhart, PharmD Derek Dr. Michael Panigot Joel Dr. Steve Wong Kathy Brooks Dr. Judy Amburgey-Peters VITA September 20, 1969 ........................... Born - Newark, Ohio May 1992 ..............................................B.S. in Pharmacy, Ohio Northern University 1996....................................................... Chairman, Graduate Student Symposium in Medicinal Chemistry The Ohio State University Spring 1999 ...........................................Lecturer, Medicinal Chemistry The Ohio State University 1992-1997 .............................................Graduate Teaching Assistant The Ohio State University 1992-2000............................................. Staff Pharmacist, Larry’s Drug Inc. 1995-2001............................................. Graduate Research Assistant The Ohio State University PUBLICATIONS Wong, M. P.; Weiss, K. L.; Curley, R. W., Jr. Recent Improvements Towards the Synthesis of the C-glucuronosyl Cancer Chemopreventive (P-D- Glucopyranosyluronate)-4-retinamidophenylmethane. J. Carbohydr. Chem. 1996, 15, 763-768. Clagett-Dame, M.; Curley, R. W., Jr.; Weiss, K. L.; Tephly, L. A.; Sikri, V. “C- Linked Analogs of A/-(4-Hydroxyphenyl)retinamide”, U.S. Patent No. 6,117,845. Weiss, K.L.; Aishafie, G.; Chapman, J.S.; Abou-lssa, H.; Clagett-Dame, M.; Curley, R.W., Jr., An Unhydrolyzable Analog of /V-(4-Hydroxyphenyl)retinamide; Synthesis and Preliminary Biological Studies, Bioorg. Med. Chem. Lett., 2001, 11, in press. VI Abou-lssa, H.; Curley, R.W., Jr.; Aishafie, G.A.; Weiss, K.L.; Clagett-Dame, M.; Chapman, J.S.; Mershon, S.M., "Chemotherapeutic Evaluation of 4-Hydroxybenzylretinone (4-HBR), a Nonhydrolyzable C-Linked Analog of A/-(4-Hydroxyphenyl)retinamide (4-HPR) Against Mammary Carcinogenesis", Anticancer Res., manuscript submitted. Weiss, K. L.; Curley, R. W., Jr., “Synthesis and Evaluation of 4- Hydroxybenzylretinone: A Structural Probe of Retinoid Action”,(manuscript in preparation) FIELDS OF STUDY Major Field: Pharmacy Specialization: Medicinal Chemistry VII TABLE OF CONTENTS Page ABSTRACT........................................................................................................................ Il DEDICATION....................................................................................................................IV ACKNOWLEDGMENTS.................................................................................................. V V IT A ................................................................................................................................... VI LIST OF TABLES........................................................................................................... XII LIST OF FIGURES........................................................................................................XIII LIST OF ABBREVIATIONS........................................................................................XVII CHAPTER 1 ....................................................................................................................... 1 INTRODUCTION...........................................................................................................1 1.1 The Discovery of Vitamin A ...........................................................................1 1.2 Retinoid Nomenclature ...................................................................................2 1.3 Properties of the Naturally Occurring Retinoids ........................................5 1.3.1 Stability, Handling, and Storage .......................................................... 5 1.3.2 Solubility ...................................................................................................6 1.3.3 Ultraviolet-Visible Spectrophotometry ................................................ 6 1.3.4 Nuclear Magnetic Resonance Spectroscopy of Retinoids ..............7 1.4 Retinol Processing ......................................................................................... 8 1.4.1 Intestinal Absorption of Dietary Vitamin A ..........................................8 1.4.2 Transport and Storage of Retinol ......................................................12 1.4.3 Retinoic Acid Biosynthesis ................................................................. 14 1.5 Biological Functions of Retinoids .............................................................. 14 1.5.1 G row th...................................................................................................16 1.5.2 Differentiation ........................................................................................16 1.5.3 Vision ..................................................................................................... 17 1.5.4 Reproduction .........................................................................................20 1.5.5
Load more

Recommended publications
  • Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems
    pharmaceutics Review Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems Gemma Latter 1, Jeffrey E. Grice 2, Yousuf Mohammed 2 , Michael S. Roberts 2,3 and Heather A. E. Benson 1,* 1 School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth 6845, Australia; [email protected] 2 Therapeutics Research Group, The University of Queensland Diamantina Institute, School of Medicine, University of Queensland, Translational Research Institute, Brisbane 4109, Australia; jeff[email protected] (J.E.G.); [email protected] (Y.M.); [email protected] (M.S.R.) 3 School of Pharmacy and Medical Sciences, University of South Australia, Basil Hetzel Institute for Translational Health Research, Adelaide 5011, Australia * Correspondence: [email protected]; Tel.: +61-8-9266-2338 Received: 19 August 2019; Accepted: 17 September 2019; Published: 24 September 2019 Abstract: Acne vulgaris is a common inflammatory pilosebaceous condition that affects 80–90% of adolescents. Since the introduction of tretinoin over 40 years ago, topical retinoid products have been a mainstay of acne treatment. The retinoids are very effective in addressing multiple aspects of the acne pathology as they are comedolytic and anti-inflammatory, and do not contribute to antibiotic resistance or microbiome disturbance that can be associated with long-term antibiotic therapies that are a common alternative treatment. However, topical retinoids are associated with skin dryness, erythema and pain, and may exacerbate dermatitis or eczema. Thus, there is a clear need to target delivery of the retinoids to the pilosebaceous units to increase efficacy and minimise side effects in surrounding skin tissue.
    [Show full text]
  • Vitamin a Deficiency and Night Blindness by John E
    VITAMIN A DEFICIENCY AND NIGHT BLINDNESS BY JOHN E. DOWLING AND GEORGE WALD* BIOLOGICAL LABORATORIES OF HARVARD UNIVERSITY, CAMBRIDGE Communicated May 16, 1958 One of the oldest diseases known to man is nutritional night blindness. Its descriptions go back to the ancient Egyptian medical papyri and are already ac- companied by the correct prescription for its cure, the eating of liver. Toward the end of World War I the factor in liver which cures night blindness was identified with the then newly discovered vitamin A.1 Vitamin A is the precursor in the retina of the visual pigments of the rods and cones.2 It seems reasonable to suppose that on a diet deficient in this factor the retina eventually synthesizes subnormal amounts of visual pigment, with the corresponding decline of visual sensitivity that constitutes night blindness. Some of the first studies of experimental human night blindness seemed to reveal such a simple and direct relationship.' In two subjects deprived of vitamin A, the visual thresholds of both rods and cones began at once to rise, until a mild night blindness had been established.4 On oral administration of vitamin A or carotene, the thresholds of both rod and cone vision returned to normal within 2-3 hours. It looked for a time, therefore, as though this might be an exemplary instance of the origin and cure of a biochemical disease, all elements of which were well under- stood. Further studies, however, exposed two major discrepancies: (1) Though in some subjects placed on a vitamin A-deficient diet the visual threshold began at once to rise, in a larger number it remained unchanged for periods ranging from several months5 to, in one instance, 2 years.6 (2) Among the subjects who developed night blindness, some were completely cured within a few hours after receiving vitamin A, whereas others, though showing some immediate improvement, took months of vitamin A supplementation to return to normal.
    [Show full text]
  • Shedding New Light on the Generation of the Visual Chromophore PERSPECTIVE Krzysztof Palczewskia,B,C,1 and Philip D
    PERSPECTIVE Shedding new light on the generation of the visual chromophore PERSPECTIVE Krzysztof Palczewskia,b,c,1 and Philip D. Kiserb,d Edited by Jeremy Nathans, Johns Hopkins University School of Medicine, Baltimore, MD, and approved July 9, 2020 (received for review May 16, 2020) The visual phototransduction cascade begins with a cis–trans photoisomerization of a retinylidene chro- mophore associated with the visual pigments of rod and cone photoreceptors. Visual opsins release their all-trans-retinal chromophore following photoactivation, which necessitates the existence of pathways that produce 11-cis-retinal for continued formation of visual pigments and sustained vision. Proteins in the retinal pigment epithelium (RPE), a cell layer adjacent to the photoreceptor outer segments, form the well- established “dark” regeneration pathway known as the classical visual cycle. This pathway is sufficient to maintain continuous rod function and support cone photoreceptors as well although its throughput has to be augmented by additional mechanism(s) to maintain pigment levels in the face of high rates of photon capture. Recent studies indicate that the classical visual cycle works together with light-dependent pro- cesses in both the RPE and neural retina to ensure adequate 11-cis-retinal production under natural illu- minances that can span ten orders of magnitude. Further elucidation of the interplay between these complementary systems is fundamental to understanding how cone-mediated vision is sustained in vivo. Here, we describe recent
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% Cream Without Compromising Efficacy in Patients with Acne
    Poster 101 Moisturizer Use Enhances Facial Tolerability of Tazarotene 0.1% Cream Without Compromising Efficacy in Patients With Acne Vulgaris Emil Tanghetti,1 Zoe Draelos,2 Pearl Grimes,3 Sunil Dhawan,4 Michael Gold,5 Leon Kircik,6 Lawrence Green,7 Angela Moore,8 Fran Cook-Bolden9 1Center for Dermatology and Laser Surgery, Sacramento, CA; 2Dermatology Consulting Services, High Point, NC; 3Vitiligo & Pigmentation Institute of Southern California, Los Angeles, CA; 4Center for Dermatology, Cosmetic and Laser Surgery, Fremont, CA; 5Tennessee Clinical Research Center, Nashville, TN; 6Physicians Skin Care PLLC, Louisville, KY; 7The George Washington University, Washington, DC; 8Arlington Center for Dermatology, Arlington, TX; 9The Skin Specialty Group, New York, NY • 6 months for systemic retinoids Table 1. Scale used to assess overall disease severity. • Mean levels of compliance were between “mostly compliant” and Efficacy Tolerability INTRODUCTION “very compliant” in both groups throughout the study. There were Score Overall disease severity no significant between-group differences in the degree of • The reduction in lesion counts with tazarotene + moisturizer was at • No adverse events considered probably or definitely related to treatment The use of any topical retinoid can involve a period of “retinization” in the first Treatment regimen 0 None—clear, no inflammatory lesions compliance. least as great as that with tazarotene alone at week 16: were reported. few weeks of treatment while the skin is adapting to the retinoid. During this • Patients were randomly assigned (on a 1:2 basis) to one of the following 1 Sparse comedones, with very few or no inflammatory lesions present period of acclimatization, some patients transiently experience dryness, – 57% vs.
    [Show full text]
  • 4-Hydroxyphenyiretinamide
    Handbook 4 4-Hydroxyphenyiretinamide 1. Chemical and Physical Melting-point Characteristics 173-175 °C (Shealy etal., 1984; Budavari etal., 1996) 1.1. Nomenclature Solubility See General Remarks, section 1.4. Soluble in most organic solvents, fats, oils and aqueous micellar solutions; sparingly soluble in 1.2 Name water, e.g. 13 nmol/L at pH 6.5 (Li et al., 1996). Chemical Abstracts Services Registry Number 65646-68-6 Spectroscopy 1% UV and visible: ? 362 (methanol), E 1 IUPAC systematic name 1225, EM 47 900 (Budavari et al., 1996; Barua & N-[4-(all-E)-9, 13-Dimethyl-7-(1, 1,5-trimethylcy- Fun, 1998). Higher EM values, i.e. 57 100 and 56 clohex-5 -en-6-yl)nona- 7,9,11,1 3-tetraen- 15- 400, have also been reported (Formelli et al., 1996). oyl]aminophenol or N-[4-(all E)-3, 7-dimethyl-9- (2,2,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8- Nuclear magnetic resonance: tetraen-1-oyl]aminophenol 'H-NMR [(CD3)SO4, 100 MHz]: 8 1.03 (1,1-CH3), 1.3-1.8 (2-CH2, 3-CH), 1.70 (5-CH), 1.8-2.2 Synonyms (4-CH2), 1.99 (9-CH), 2.36 (13-CH), 6.03 (14-H), Fenretinide, 4-HPR, N-(4-hydroxyphenyl)reti- 6.1-6.6 (7-H, 8-H, 10-H, 12-H), 6.99 (11-H), namide, hydroxyphenyl-retinamide, N-(4-hydro- 6.6-6.8 and 7.3-7.6 (benzene ring -H), 9.15 (NH), xyphenyl)retinamide, N-(4-hydroxyphenyl)-all- 9.74 (OH) (Coburn et al., 1983; Shealy et al., tnins-retinamide 1984).
    [Show full text]
  • DF Fall 2019-Webready
    A DERMATOLOGY FOUNDATION PUBLICATION SPONSORED BY ORTHO DERMATOLOGICS VOL. 38 NO. 2 FALL 2019 DDEERRMMAATTOOLLOOGGYY ™ Also In This Issue FOCUSFOCUS Janet Fairley, MD, New DF President: “DF support has profoundly advanced our specialty.” DF Clinical Symposia: Stiefel Scholar Cancer Research— Proceedings 2019–Part II Aiming to Normalize KC Cells Explaining that the child’s skin barrier has a structural defect enables ADVANCES IN DERMATOLOGY parents to understand the involvement of inadequate hydration, more bacteria, and increased penetration of antigens and allergens. Then The Dermatology Foundation presented its Maguiness explains the need to simultaneously treat the dehydrated annual 3-day cutting-edge CME symposia series skin, itch, inflammation, and infection, and teaches parents the entire earlier this year. Informal Breakfast Roundtables 2-week topical “eczema boot camp” routine: bleach baths, topical and evening Therapeutics Forums amplified the steroids, emollients, and wet wraps, typically done at home. She reassuringly likens a bleach bath to a swimming pool. Maguiness take-home value. Part II of the Proceedings includes described the procedures and benefits of bleach baths and wet wraps Therapeutic Updates; Diagnostic Dilemmas; and in detail, provided practical tips for gaining parental confidence and Medical Dermatology. (Part I, which appeared understanding, noted variations to the overall “boot camp” routine, and in the previous issue, included the Keynote talk discussed tapering. Then she shared her excitement about “entering
    [Show full text]
  • Introduction; Environment & Review of Eyes in Different Species
    The Biological Vision System: Introduction; Environment & Review of Eyes in Different Species James T. Fulton https://neuronresearch.net/vision/ Abstract: Keywords: Biological, Human, Vision, phylogeny, vitamin A, Electrolytic Theory of the Neuron, liquid crystal, Activa, anatomy, histology, cytology PROCESSES IN BIOLOGICAL VISION: including, ELECTROCHEMISTRY OF THE NEURON Introduction 1- 1 1 Introduction, Phylogeny & Generic Forms 1 “Vision is the process of discovering from images what is present in the world, and where it is” (Marr, 1985) ***When encountering a citation to a Section number in the following material, the first numeric is a chapter number. All cited chapters can be found at https://neuronresearch.net/vision/document.htm *** 1.1 Introduction While the material in this work is designed for the graduate student undertaking independent study of the vision sensory modality of the biological system, with a certain amount of mathematical sophistication on the part of the reader, the major emphasis is on specific models down to specific circuits used within the neuron. The Chapters are written to stand-alone as much as possible following the block diagram in Section 1.5. However, this requires frequent cross-references to other Chapters as the analyses proceed. The results can be followed by anyone with a college degree in Science. However, to replicate the (photon) Excitation/De-excitation Equation, a background in differential equations and integration-by-parts is required. Some background in semiconductor physics is necessary to understand how the active element within a neuron operates and the unique character of liquid-crystalline water (the backbone of the neural system). The level of sophistication in the animal vision system is quite remarkable.
    [Show full text]
  • The Conformation of the Β-Ionone Ring Region of the Chromophore of Rhodopsin, in the Dark and Meta-I Photostates
    The conformation of the β-ionone ring region of the chromophore of rhodopsin, in the dark and meta-I photostates Jonathan M. Sharples Submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy Corpus Christi College, Oxford Hilary, 2003 Abstract The conformation of the β-ionone ring region of the chromophore of rhodopsin, in the dark and meta-I photostates Jonathan M. Sharples D.Phil Thesis Corpus Christi College Hilary 2003 Rhodopsin is the light-sensitive GPCR that triggers the signal transduction cascade that results in a visual response. It serves as a paradigm for the superfamily of transmembrane G- protein coupled receptors (GPCR), which are responsible for many cell signal transduction pathways and are a major family of drug targets. Upon excitation with light, photo- isomerization of the 11-Z-retinylidene chromophore to 11-E-retinylidene activates rhodopsin, through a series of transient photointermediates. Defining the detailed structure of retinal within its binding site in rhodopsin is essential for a functional understanding of rhodopsin activation and an understanding of the general mechanism of GPCR activation. Here, solid state NMR has been applied to deduce the conformation of the β-ionone ring of 13 13 the chromophore of rhodopsin, in non-perturbing [8,18- C2] 11-Z retinal and [8,16/17- C2] 11-Z retinal, regenerated into rhodopsin in rod outer segments (ROS). The rotational resonance NMR technique was used to measure the internuclear distance between a 13C labelled nucleus on the polyene chain (C8) and three 13C labelled methyl groups (C16, C17 and C18) on the β-ionone ring of the chromophore.
    [Show full text]
  • TAZORAC® (Tazarotene) Gel 0.05% (Tazarotene) Gel 0.1%
    NDA 020600 ® TAZORAC (tazarotene) Gel 0.05% (tazarotene) Gel 0.1% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE DESCRIPTION TAZORAC® Gel is a translucent, aqueous gel and contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical dermatologic use only. The active ingredient is represented by the following structural formula: O OCH2CH3 N S TAZAROTENE C21H21NO2S Molecular Weight: 351.46 Chemical Name: Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate Contains: Active: Tazarotene 0.05% or 0.1% (w/w) Preservative: Benzyl alcohol 1% (w/w) Inactives: Ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, carbomer 934P, edetate disodium, hexylene glycol, poloxamer 407, polyethylene glycol 400, polysorbate 40, purified water, and tromethamine. CLINICAL PHARMACOLOGY Tazarotene is a retinoid prodrug which is converted to its active form, the cognate carboxylic acid of tazarotene (AGN 190299), by rapid deesterification in animals and man. AGN 190299 (“tazarotenic acid”) binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings is unknown. Psoriasis: The mechanism of tazarotene action in psoriasis is not defined. Topical tazarotene blocks induction of mouse epidermal ornithine decarboxylase (ODC) activity, which is associated with cell proliferation and hyperplasia. In cell culture and in vitro models of skin, tazarotene suppresses expression of MRP8, a marker of inflammation present in the epidermis of psoriasis patients at high levels. In human keratinocyte cultures, it inhibits cornified envelope formation, whose build-up is an element of the psoriatic scale.
    [Show full text]
  • Microencapsulation of Amorphous Solid Dispersions of Fenretinide Enhances Drug Solubility and Release from PLGA in Vitro and in Vivo T ⁎ Kari Nietoa, Susan R
    International Journal of Pharmaceutics 586 (2020) 119475 Contents lists available at ScienceDirect International Journal of Pharmaceutics journal homepage: www.elsevier.com/locate/ijpharm Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo T ⁎ Kari Nietoa, Susan R. Malleryb, Steven P. Schwendemana,c, a Department of Pharmaceutical Sciences and The Biointerfaces Institute, University of Michigan, Ann Arbor, MI, United States b Division of Oral Maxillofacial Pathology & Radiology, College of Dentistry, Ohio State University, Columbus, OH, United States c Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States ARTICLE INFO ABSTRACT Keywords: The purpose of this study was to develop solid dispersions of fenretinide(4HPR), incorporate them into poly Fenretinide (4HPR) (lactic-co-glycolic)(PLGA) millicylindrical implants, and evaluate the resulting implants in vitro and in vivo for polyvinylpyrrolidone (PVP) future applications in oral cancer chemoprevention. Due to the extreme hydrophobicity of 4HPR, 4HPR-poly- amorphous solid dispersion (ASD) vinylpyrrolidone (PVP) amorphous solid dispersions(ASDs) were prepared for solubility enhancement. The Solubility enhancement optimal PVP-4HPR ratio of 9/1(w/w) provided a 50-fold solubility enhancement in aqueous media, which was Poly(lactic-co-glycolic) (PLGA) sustained over 1 week. PVP-4HPR ASD particles were loaded into PLGA millicylinders and drug release was In vivo release long-acting release (LAR) evaluated in vitro in PBST and in vivo by recovery from subcutaneous injection in rats. While initial formulations of PLGA PVP-4HPR millicylinders only released 10% 4HPR in vitro after 28 days, addition of the plasticizer triethyl-o-acetyl-citrate(TEAC) into PVP-4HPR ASDs resulted in a 5.6-fold total increase in drug release.
    [Show full text]
  • Agonist and Antagonist of Retinoic Acid Receptors Cause Similar Changes in Gene Expression and Induce Senescence-Like Growth Arrest in MCF-7 Breast Carcinoma Cells
    Research Article Agonist and Antagonist of Retinoic Acid Receptors Cause Similar Changes in Gene Expression and Induce Senescence-like Growth Arrest in MCF-7 Breast Carcinoma Cells Yuhong Chen,1 Milos Dokmanovic,1 Wilfred D. Stein,1,2 Robert J. Ardecky,3 and Igor B. Roninson1 1Cancer Center, Ordway Research Institute, Albany, New York; 2Institute of Life Sciences, Hebrew University, Jerusalem, Israel; and 3Ligand Pharmaceuticals, Inc., San Diego, California Abstract retinoids is most often attributed to the induction of differentia- Biological effects of retinoids are mediated via retinoic acid tion, but these compounds were also shown to stop the growth of (RA) receptors (RAR) and retinoid X receptors (RXR). The tumor cells by inducing apoptosis or accelerated senescence (1, 2). best-characterized mechanism of retinoid action is stimula- In particular, treatment of two human breast carcinoma cell lines tion of transcription from promoters containing RA response with all-trans retinoic acid (RA) or fenretinide, in vitro or in vivo, elements (RARE). Retinoids induce senescence-like growth induces a senescence-like phenotype characterized by increased h arrest in MCF-7 breast carcinoma cells; this effect is cell size and expression of senescence-associated -galactosidase h associated with the induction of several growth-inhibitory (SA- -gal; refs. 3, 4). This phenotype, as investigated in MCF-7 cells, genes. We have nowfound that these genes are induced by is associated with irreversible growth arrest and up-regulation of RAR-specific but not by RXR-specific ligands. Genome-scale several intracellular and secreted proteins with known growth- microarray analysis of gene expression was used to compare inhibitory activities.
    [Show full text]